Wednesday, June 13, 2012
Cempra Inc., of Chapel Hill, N.C., dosed the first two patients in its Phase II trial evaluating the efficacy, safety and tolerability of solithromycin in uncomplicated urogenital gonococcal infections.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.